Valeant Pharmaceuticals International Inc. (VRX) on Wednesday said it paid down another $300 million of its senior secured term loans, paring its debt load to about $25.7 billion at the end of 2017.
The struggling pharmaceutical giant said it has reduced its debt by more than $6.5 billion since the end of the first quarter of 2016.
Valeant has been beset by corporate turbulence since 2015, a span when its drug-price increases and accounting were attacked, top executives were ousted, and its market capitalization nose-dived.
"We have reduced our debt by an additional $300 million due to ongoing strong cash flow from operations," Valeant said, adding that it will continue to invest in core businesses in 2018.
Valeant shares rose 2.6% in early trading Wednesday.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
January 03, 2018 09:53 ET (14:53 GMT)